Analysis of the questionnaire on Kidney Disease: Improving Global Outcomes chronic kidney disease-mineral and bone disorder in Shanghai

CHEN Xiaonong,CHEN Zijin,HAO Chuanming,YUAN Weijie,NI Zhaohui,YE Zhibin,DING Xiaoqiang,HE Liqun,ZHANG Jinyuan,ZHANG Yun,MEI Changlin,CHEN Nan
2012-01-01
Abstract:Objective To survey the clinic practices of Kidney Disease Outcomes Quality Initiative (KDOQI) and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines on chronic kidney disease-mineral and bone disorder (CKD-MBD) in 54 hospitals in Shanghai. Methods CKD-MBD questionnaires were sent to 54 hospitals in Shanghai, including 54 department questionnaires and 261 physician questionnaires. Results Our survey achieved a 100.0% response rate for department questionnaires and 84.7% for physician questionnaires. In all the 54 hospitals, the treatment of CKD-MBD was based on KDOQI guideline in 22.2% hospitals, on KDIGO guideline in 20.4% hospitals and on both guidelines in 57.4% hospitals. Guidelines were successfully performed in 55.6% hospitals. There was a higher proportion of successful implementation for guidelines in grade-three hospitals as compared with grade-two hospitals (P<0.05). Blood biochemical examinations were well developed. 42.6% hospitals developed 25(OH) D3 test, 53.7% hospitals made coronary CT angiography and lateral lumbar X-ray, while only 18.5% hospitals developed bone-specific alkaline phosphatase (ALP) test. Serum phosphate maintained in 0.80-1.78 mmol/L in 39.6% maintenance hemodialysis (MHD) patients, serum calcium was in 2.10-2.54 mmol/L in 53.5% MHD patients, and parathyroid hormone (PTH) ranged 150-300 pg/mL in 34.1% MHD patients. Calcium carbonate was used in 92.6% hospitals for MHD patients with hyperphosphatemia. Severe secondary hyperparathyroidism in MHD patients were treated by surgery in 38.9% hospitals. Conclusion Nephrologists in Shanghai take KDOQI and KDIGO as main clinical practice guidelines. Blood biochemical examinations are well developed in grade-three hospitals. But it is important to improve the monitoring of bone-specific ALP, 25 (OH) D3 and the detection of vascular calcification. There is a high prevalence of hyperphosphatemia in MHD patients, and effective phosphate-binder for the treatment is needed.
What problem does this paper attempt to address?